Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Tumor Biology 14: Signaling and Angiogenesis

Preclinical chemotherapy with the VEGFR-2 and PDGFR inhibitor, BAY 57-9352, in combination with Capecitabine and Paclitaxel

Yong S. Chang, Christian Cortes, Barbara Polony, Cheryl Brink* and James J. Elting
Yong S. Chang
Bayer Corp., West Haven, CT and * Arqule, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Cortes
Bayer Corp., West Haven, CT and * Arqule, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara Polony
Bayer Corp., West Haven, CT and * Arqule, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheryl Brink*
Bayer Corp., West Haven, CT and * Arqule, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James J. Elting
Bayer Corp., West Haven, CT and * Arqule, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2005
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 46, 2005

Abstract

2030

BAY 57-9352 is an orally active, small molecule inhibitor of VEGFR-2 and PDGFR-b tyrosine kinases, which is currently in Phase I clinical trials. BAY 57-9352 blocks tumor growth through the inhibition of these key regulators of tumor angiogenesis. It exhibits a broad-spectrum of activity as a single agent in multiple human tumor xenograft models representing breast, colon, prostate and lung cancer. The clinical development of BAY 57-9352 is anticipated to include combination chemotherapy with the current standards of care for a variety of histological types of cancer. In the current studies, we have examined the anti-tumor activity and tolerability of BAY 57-9352 when co-administered with either capecitabine (Xeloda® ) or paclitaxel (Taxol® ). The anti-tumor efficacy and tolerability of BAY 57-9352 in combination with capecitabine or paclitaxel were examined using subcutaneous Colo-205 human colorectal cancer or H460 human non-small cell lung cancer xenograft models, respectively, implanted in female athymic (NCr-nu/nu) mice. In two studies combining BAY 57-9352 with capecitabine, both agents were administered p.o. for 9 or 10 days. When combined with paclitaxel, BAY 57-9352 was administered p.o. for 9 days and paclitaxel was administered concurrently (i.v.) for the first 5 days. Efficacy was assessed as the days delay in tumor growth to reach a specified size (TGD). BAY 57-9352 (60 mg/kg, p.o.) and capecitabine (500 mg/kg, p.o.) demonstrated significant anti-tumor activity following once daily administration as single agents in the Colo-205 model with an average TGD of 16 and 30 days, respectively. Combination of these agents showed an average TGD of 40 days with no toxicity. Combination of BAY 57-9352 with paclitaxel required reduction of BAY 57-9352 from 60 mg/kg to 40 mg/kg to achieve acceptable tolerability. In the H460 model, BAY 57-9352 (40 mg/kg, p.o.) and paclitaxel (15 mg/kg, i.v.) exhibited anti-tumor activity as single agents with a TGD of 6 days and 10 days, respectively. When combined, these agents produced a TGD of 14 days and demonstrated acceptable toxicity. In all studies, the combination of BAY 57-9352 with capecitabine or paclitaxel was at least as effective as the individual agents administered alone. The results of these studies support the combination of BAY 57-9352 with either capecitabine or paclitaxel in clinical studies with these agents.

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 65 (9 Supplement)
May 2005
Volume 65, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Preclinical chemotherapy with the VEGFR-2 and PDGFR inhibitor, BAY 57-9352, in combination with Capecitabine and Paclitaxel
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Preclinical chemotherapy with the VEGFR-2 and PDGFR inhibitor, BAY 57-9352, in combination with Capecitabine and Paclitaxel
Yong S. Chang, Christian Cortes, Barbara Polony, Cheryl Brink* and James J. Elting
Cancer Res May 1 2005 (65) (9 Supplement) 475;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Preclinical chemotherapy with the VEGFR-2 and PDGFR inhibitor, BAY 57-9352, in combination with Capecitabine and Paclitaxel
Yong S. Chang, Christian Cortes, Barbara Polony, Cheryl Brink* and James J. Elting
Cancer Res May 1 2005 (65) (9 Supplement) 475;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice
  • HER2 signaling regulates different angiogenic factors through different pathways in breast cancer cells
Show more Tumor Biology 14: Signaling and Angiogenesis
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement